Emerging NY Biotech Furthers Sanofi’s CNS Therapeutics

A novel New York-based biotech managed to impress Sanofi, snatching a deal to obtain two Phase III CNS pipelines. In a brief press release, not much was disclosed about the scope of the deal, it included an upfront payment, but specific financial details of the deal were not revealed.

Terran Biosciences, dedicated to the development of transformational therapeutics for neurological diseases, secured the agreement with Sanofi for exclusive global rights to develop and market said two late-stage CNS assets. These therapeutics generated 4 Investigational New Drug (IND) applications and more than 104 clinical studies involving over 15,000 subjects across numerous CNS indications.

Terran plans to rapidly advance development of these new pipelines for neurological and psychiatric indications with novel applications for large unmet medical demands. This transaction represents a major next stage in the development of these promising portfolios.

“We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry,” said Dr. Sam Clark, Terran’s Founder and CEO.

Related Article: Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Mysterious NY Biotech

Equipped with a bare corporate webpage, little is known about Terran Biosciences. Known investors include Noetic Fund and Catalytic Impact Foundation. The biotech also popped up in March recently to sign a CNS “portfolio” and intellectual properties deal with Concert.

Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing a number of late-stage assets, which include novel psychedelic-based therapeutics.

Author

Fujie Tham